Marica Anderle

Marica Anderle

Auto-generated profile, based on publicly available information

Marica Anderle

Armenise-Harvard Laboratory of Brain Cancer, Department CIBIO, University of Trento, Via Sommarive 9, 38123 Trento, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CBClaudio Ballabio
Claudio Ballabio
MAMarica Anderle
Marica Anderle
MGMatteo Gianesello
Matteo Gianesello
CLChiara Lago
Chiara Lago
Evelina MieleEvelina Miele
Evelina Miele
LTLuca Tiberi
Luca Tiberi
Medulloblastoma (MB) is the most common malignant brain tumor in children and among the subtypes, Group 3 MB has the worst outcome. Here, we perform an in vivo, patient-specific screen leading to the identification of Otx2 and c-MYC as strong Group 3 MB inducers. We validated our findings in human cerebellar organoids where Otx2/c-MYC give rise to MB-like organoids harboring a DNA methylation signature that clusters with human Group 3 tumors. Furthermore, we show that SMARCA4 is able to reduce Otx2/c-MYC tumorigenic activity in vivo and in human cerebellar organoids while SMARCA4 T910M, a mutant form found in human MB patients, inhibits the wild-type protein function. Finally, treatment with Tazemetostat, a EZH2-specific inhibitor, reduces Otx2/c-MYC tumorigenesis in ex vivo culture and human cerebellar organoids. In conclusion, human cerebellar organoids can be efficiently used to understand the role of genes found altered in cancer patients and represent a reliable tool for developing personalized therapies.

23 August 2017 in Nature
Verified
Journal Article
Open access
PDF file
KPKathrin Pieper
Kathrin Pieper
JTJoshua Tan
Joshua Tan
LPLuca Piccoli
Luca Piccoli
MFMathilde Foglierini
Mathilde Foglierini
SBSonia Barbieri
Sonia Barbieri
ALAntonio Lanzavecchia
Antonio Lanzavecchia
Up to 10% of individuals in malaria-endemic regions produce antibodies that react to malaria antigens through an additional LAIR1 domain that is inserted by two different insertion modalities. Antonio Lanzavecchia and colleagues show that in malaria endemic regions, 5% to 10% of exposed individuals have antibodies directed against a type of variant antigen expressed on the surface of cells infected with Plasmodium falciparum that have an insertion of the LAIR1 domain. For comparison, less than 0.01% of the European blood donors showed very low levels of such antibodies. Insertion of templated DNA into either the VDJ or IgH switch region of the antibody generates antibodies with two distinct binding specificities and represents an additional mechanism of antibody diversification. In two previously described donors, the extracellular domain of LAIR1, a collagen-binding inhibitory receptor encoded on chromosome 19 (ref. 1), was inserted between the V and DJ segments of an antibody. This insertion generated, through somatic mutations, broadly reactive antibodies against RIFINs, a type of variant antigen expressed on the surface of Plasmodium falciparum-infected erythrocytes2. To investigate how frequently such antibodies are produced in response to malaria infection, we screened plasma from two large cohorts of individuals living in malaria-endemic regions. Here we report that 5–10% of malaria-exposed individuals, but none of the European blood donors tested, have high levels of LAIR1-containing antibodies that dominate the response to infected erythrocytes without conferring enhanced protection against febrile malaria. By analysing the antibody-producing B cell clones at the protein, cDNA and gDNA levels, we characterized additional LAIR1 insertions between the V and DJ segments and discovered a second insertion modality whereby the LAIR1 exon encoding the extracellular domain and flanking intronic sequences are inserted into the switch region. By exon shuffling, this mechanism leads to the production of bispecific antibodies in which the LAIR1 domain is precisely positioned at the elbow between the VH and CH1 domains. Additionally, in one donor the genomic DNA encoding the VH and CH1 domains was deleted, leading to the production of a camel-like LAIR1-containing antibody. Sequencing of the switch regions of memory B cells from European blood donors revealed frequent templated inserts originating from transcribed genes that, in rare cases, comprised exons with orientations and frames compatible with expression. These results reveal different modalities of LAIR1 insertion that lead to public and dominant antibodies against infected erythrocytes and suggest that insertion of templated DNA represents an additional mechanism of antibody diversification that can be selected in the immune response against pathogens and exploited for B cell engineering.

1 December 2019 in Cell Reports
Verified
Journal Article
Open access
GAGiuseppe Aiello
Giuseppe Aiello
CBClaudio Ballabio
Claudio Ballabio
RRRiccardo Ruggeri
Riccardo Ruggeri
LFLuca Fagnocchi
Luca Fagnocchi
MAMarica Anderle
Marica Anderle
LTLuca Tiberi
Luca Tiberi
The transition of neural progenitors to differentiated postmitotic neurons is mainly considered irreversible in physiological conditions. In the present work, we show that Shh pathway activation through SmoM2 expression promotes postmitotic neurons dedifferentiation, re-entering in the cell cycle and originating medulloblastoma in vivo. Notably, human adult patients present inactivating mutations of the chromatin reader BRPF1 that are associated with SMO mutations and absent in pediatric and adolescent patients. Here, we found that truncated BRPF1 protein, as found in human adult patients, is able to induce medulloblastoma in adult mice upon SmoM2 activation. Indeed, postmitotic neurons re-entered the cell cycle and proliferated as a result of chromatin remodeling of neurons by BRPF1. Our model of brain cancer explains the onset of a subset of human medulloblastoma in adult individuals where granule neuron progenitors are no longer present.

25 June 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
CBClaudio Ballabio
Claudio Ballabio
MGMatteo Gianesello
Matteo Gianesello
CLChiara Lago
Chiara Lago
KOKonstantin Okonechnikov
Konstantin Okonechnikov
MAMarica Anderle
Marica Anderle
LTLuca Tiberi
Luca Tiberi
The identity of the cell of origin is a key determinant of cancer subtype, progression, and prognosis. Group 3 medulloblastoma (MB) is a malignant childhood brain cancer with poor prognosis and few candidates as putative cell of origin. We overexpressed the group 3 MB genetic drivers MYC and Gfi1 in different candidate cells of origin in the postnatal mouse cerebellum. We found that S100b+ cells are competent to initiate group 3 MB, and we observed that S100b+ cells have higher levels of Notch1 pathway activity compared to Math1+ cells. We found that additional activation of Notch1 in Math1+ and Sox2+ cells was sufficient to induce group 3 MB upon MYC/Gfi1 expression. Together, our data suggest that the Notch1 pathway plays a critical role in group 3 MB initiation.